

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

1-45. (Canceled)

46. (Previously presented) A method for administering a therapeutic agent within the central nervous system of a subject, the method comprising intrathecally administering a composition to the central nervous system of said subject, wherein said composition comprises a plurality of biodegradable polymer particles having a therapeutic agent and a buoyancy agent contained therein, wherein the buoyancy agent is a gas or an oil, or a combination thereof, and wherein the composition is controllably buoyant within the cerebrospinal fluid to provide targeted delivery of the therapeutic agent within the central nervous system of the subject, wherein the buoyancy agent comprises a hydrofluorocarbon.

47-54. (Canceled)

55. (Previously presented) The method of claim 46, wherein said subject is diagnosed with a central nervous system disorder.

56. (Previously presented) The method of claim 46, wherein said composition is in the form of a plurality of spherical particles from about 1 to about 25 μm in diameter.

57. (Previously presented) The method of claim 46, wherein the therapeutic agent is selected from the group consisting of L-dopa, dopamine, carbidopa, choline, acetyl choline, cholinergic neuronotropic agents, gangliosides, nerve growth enhancing agents, living cells, enzymes, antipsychotropic agents, antidepressants, excitatory amino acid antagonist or agonist, antiepileptic medications, and combinations thereof as well as antioxidants, nonsteroidal anti-inflammatory drugs (NSAIDS), steroidal anti-inflammatory agents, calcium channel blockers, N-methyl-D-aspartate (NMDA) antagonists, inosine, citicholine, superoxide dismutase, dextrorphan, aspirin, tetramethylpyrazine, antibiotics, and combinations thereof.

58. (Previously presented) The method of claim 46, wherein the therapeutic agent is a cancer agent selected from the group consisting of vinca alkaloids and other plant products, cytostatic drugs, cytotoxic drugs, hormones, alkylating agents, immunomodulators, hematological agents, radiopharmaceuticals, antibodies, antiandrogens, and epidermals.

59. (Previously presented) The method of claim 46, wherein the intrathecal administration occurs directly into the cerebrospinal fluid of the subject.

60. (Previously presented) The method of claim 55, wherein the central nervous system disorder is selected from the group consisting of cancer, Parkinson's disease, Alzheimer's dementia, Huntington's disease, epilepsy, amyotrophic lateral sclerosis, multiple sclerosis, trauma, stroke, traumatic brain injury, depression, spinal cord injury, and pain management.

61. (Previously presented) The method of claim 46, wherein said biodegradable polymer is a naturally derived polymer selected from the group consisting of albumin, alginate, cellulose, collagen, fibrin, gelatin, and polysaccharides.

62. (Previously presented) The method of claim 46, wherein said biodegradable polymer is a synthetic polymer selected from the group consisting of polyesters, polyethylene glycol, poloxomers, polyanhydrides, and pluronics.

63. (Previously presented) The method of claim 46, wherein said synthetic polymer is poly(lactide-co-glycolide).

64. (Previously presented) The method of claim 57, wherein said living cells are selected from bone marrow cells and fetal neural tissue and stem cells, and combinations thereof.

65. (Previously presented) The method of claim 58, wherein said hormones are selected from estrogens and anti-estrogens.

66. (Previously presented) The method of claim 58, wherein said immunomodulators are selected from immunostimulators and immunosuppressives.

67. (Previously presented) The method of claim 46, wherein the therapeutic agent is a neuroprotective agent and said composition is administered to a subject having a central nervous system disorder.